Elicio Therapeutics, Inc.ELTXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank67
3Y CAGR-65.1%
5Y CAGR-46.2%
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

3Y CAGR
-65.1%/yr
Annual compound
5Y CAGR
-46.2%/yr
Recent deceleration
Percentile
P67
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
20250.31%
2024-13.38%
2023-47.41%
20227.35%
2021-4.59%
20206.92%
2019-206.60%
20180.00%
201377.65%
20120.00%